Ventripoint Diagnostics to Satisfy Debenture Interest with Share Issuance
Toronto, Ontario — February 11, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV:VPT) will issue common shares to satisfy debenture interest payment obligations, pending TSX Venture Exchange (TSXV) approval.
Ventripoint will issue 291,344 common shares for an aggregate of $36,989.01 in interest on outstanding Convertible Debentures issued June 28, 2024, December 16, 2024, January 17, 2025, and February 7, 2025. The Convertible Debentures accrue interest at 10% per annum, payable every six months. The shares will be issued at a deemed price of $0.127, subject to TSXV approval, and are subject to a four-month hold period.
The debentures issued January 17, 2025, and February 7, 2025, totaling $256,000, have been converted, so no further interest is owing on those series of debentures. The issuance of shares will not create a control person of the Corporation.
Ventripoint has become an industry leader in applying AI to echocardiography. Ventripoint’s VMS products are powered by proprietary knowledge-based reconstruction technology, the result of a decade of development, and provide accurate volumetric cardiac measurements equivalent to MRI. This alternative allows cardiologists greater confidence in managing their patients.
VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
Source: Ventripoint Diagnostics Ltd.
Share this story:
